Expert Interviews

Panelist discusses how polling results show varied approaches to second-line atopic dermatitis treatment, emphasizing that topical corticosteroids remain the workforce but require proper usage limits of 1 to 2 weeks to avoid serious adverse effects, while highlighting growing patient concerns about steroid phobia and topical steroid withdrawal syndrome.

Panelist discusses how the current treatment guidelines include 4 classes of topical therapies, with newer nonsteroidal options like JAK inhibitors and PDE4 inhibitors providing effective alternatives to long-term corticosteroid use.

Panelist discusses how proper skin care forms the foundation of atopic dermatitis treatment and emphasizes the importance of proactive rather than reactive treatment approaches using maintenance therapy.

Panelist discusses how to assess atopic dermatitis severity using practical measures like body surface area, itch scores, and quality of life impact rather than complex clinical trial scoring systems.

Panelist discusses how atopic dermatitis presentation varies by age and skin tone, emphasizing that it’s a systemic condition with multiple comorbidities that can be prevented through early aggressive treatment.

Panelist discusses how the atopic dermatitis treatment landscape has evolved with new nonsteroidal topical therapies that can match the effectiveness of corticosteroids without their associated adverse effects and long-term risks.

RAD 2025: Mona Shahriari, MD, underscored the cumulative life impact of atopic dermatitis, reminding clinicians that there is always far more to the condition than meets the clinical eye.

Hear experts' takeaways from ACOG 2025 on menopause care, postpartum depression screening, and obesity management.

Only about 75% of people with a positive result on a stool-based test for colorectal cancer complete screening with a colonoscopy. Fendrick "won't rest" until it's 90%.

Mark Fendrick, MD, thinks that right now, the relative accuracy of blood-based tests for CRC compared with available alternatives is not quite comparable. He explains.